Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

A giant tortoise, extinct for over a century, has reappeared alive after several failed expeditions, reviving a historic plan to save the species, a symbol of evolution

Genetic sleuthing has now confirmed that she belongs to the Fernandina Island Galápagos giant tortoise, Chelonoidis phantasticus, a lineage thought lost since a lone male was collected in 1906.

Only two individuals of this lineage have ever been found, the museum specimen from the early twentieth century and Fernanda. To make sure she was not a stray tortoise washed in from another island, researchers sequenced her entire genome and compared it with DNA extracted from the century-old male and from all other living Galápagos tortoise species.

The analyses showed that Fernanda and the museum male form their own distinct branch, separate from the rest of the archipelago’s giants.

Chinese Researchers Clear Hurdles For Long-Distance Quantum Networks

A Chinese research team has reported a pair of advances that could remove two of the biggest technical barriers to building large-scale quantum communication networks, including the generation of ultra-secure encryption keys over 11 kilometers of optical fiber and the validation of the approach at distances up to 100 kilometers, according to China Daily, a state-associated news service.

Researchers from the University of Science and Technology of China said they have demonstrated, for the first time, a scalable core component of a quantum repeater — a long-sought technology needed to extend quantum communication across long distances — while also setting new records for ultra-secure quantum key distribution over fiber networks.

The findings were published in Nature and Science, underscoring their significance within the international research community. Noted Chinese physicist Pan Jianwei led the work.

SpaceX Starthink: Building Earth’s Planetary Neocortex with Orbital AI

In a bold fusion of SpaceX’s satellite expertise and Tesla’s AI prowess, the Starthink Synthetic Brain emerges as a revolutionary orbital data center.

Proposed in Digital Habitats February 2026 document, this next-gen satellite leverages the Starlink V3 platform to create a distributed synthetic intelligence wrapping the planet.

Following SpaceX’s FCC filing for up to one million orbital data centers and its acquisition of xAI, Starthink signals humanity’s leap toward a Kardashev II civilization.

As Elon Musk noted in February 2026, ]

“In 36 months, but probably closer to 30, the most economically compelling place to put AI will be space.”

## The Biological Analogy.

Starthink draws from neuroscience: * Neural Cluster: A single Tesla AI5 chip, processing AI inference at ~250W, like a neuron group. * Synthetic Brain: One Starthink satellite, a 2.5-tonne self-contained node with 500 neural clusters, solar power, storage, and comms. * Planetary Neocortex: One million interconnected Brains forming a global mesh intelligence, linked by laser and microwave “synapses.”

Why the Future of Intelligence Is Already Here | Alex Wissner-Gross | TEDxBoston

The future of intelligence is rapidly evolving with AI advancements, poised to transform numerous aspects of life, work, and existence, with exponential growth and sweeping changes expected in the near future.

## Questions to inspire discussion.

Strategic Investment & Career Focus.

🎯 Q: Which companies should I prioritize for investment or career opportunities in the AI era?

A: Focus on companies with the strongest AI models and those advancing energy abundance, as these will have the largest marginal impact on enabling the innermost loop of robots building fabs, chips, and AI data centers to accelerate exponentially.

Understanding Market Dynamics.

Association of a Cancer Diagnosis and Mortality After Ischemic and Hemorrhagic Stroke and Myocardial Infarction

This population-based study showed that patients with cancer had higher risks of mortality after stroke and myocardial infarction, with substantial variations by cancer type.


Background and Objectives.

Large-Scale Proteomics Reveals New Candidate Biomarkers for Late-Onset Preeclampsia

RESEARCH ARTICLE: large-scale proteomics reveals new candidate biomarkers for late-onset preeclampsia.


BACKGROUND: Preeclampsia is classified as either a more severe early onset or a more prevalent late-onset form. Lower PlGF (placental growth factor) and increased sFlt-1 (fms-like tyrosine kinase-1) in maternal circulation are promising biomarkers, yet they lack specificity for preeclampsia. METHODS: We quantified ≈7000 proteins in 673 samples collected from 89 patients with late-onset preeclampsia and 91 controls at T1 (15–22), T2 (22–30), and T3 (30–42) weeks. Elastic net and random forest models were fitted and evaluated by cross-validation. Differential abundance analysis followed by functional profiling, was used to identify and interpret protein changes. RESULTS: An increase in protein differential abundance in late-onset preeclampsia was observed with advancing gestation, reaching 806 proteins at T3 related to angiogenesis, cell adhesion, and extracellular matrix remodeling.

A single oncolytic virus injection may help T cells infiltrate glioblastoma

A team led by investigators at Mass General Brigham and Dana-Farber Cancer Institute has shown that a single injection of an oncolytic virus—a genetically modified virus that selectively infects and destroys cancer cells—can recruit immune cells to penetrate and persist deep within brain tumors. The research, which is published in Cell, provides details on how this therapy prolonged survival in patients with glioblastoma, the most common and malignant primary brain tumor, in a recent clinical trial.

“Patients with glioblastoma have not benefited from immunotherapies that have transformed patient care in other cancer types such as melanoma because glioblastoma is a ‘cold’ tumor with poor infiltration by cancer-fighting immune cells,” said co-senior author Kai Wucherpfennig, MD, Ph.D., chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute.

“Findings from our clinical trial and our mechanistic study show that it is now feasible to bring these critical immune cells into glioblastoma.”

Abstract: Osimertinib (Osi) is first-line treatment for metastatic lung adenocarcinoma with EGFR mutations

Here, Jonathan M. Kurie & team show Osi-resistant cancer secrete effector proteins that increase the metastatic properties of drug-naive cells and influence lung cancer progression through paracrine mechanisms:

The figure shows Osi-resistant (OR) cells show Golgi remodeling compared with drug-naïve (DN) cells.


1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas–MD Anderson Cancer Center, Houston, Texas, USA.

2Section of Hematology and Medical Oncology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.

3Tulane Cancer Center, Louisiana Cancer Research Center, New Orleans, Louisiana, USA.

/* */